Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity

DOI record: { "DOI": "10.3389/fmicb.2022.952321", "ISSN": [ "1664-302X" ], "URL": "http://dx.doi.org/10.3389/fmicb.2022.952321", "abstract": "<jats:p>Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of <jats:italic>Streptomyces avermitilis</jats:italic>. <jats:italic>Bifidobacterium</jats:italic> is a member of the same phylum as <jats:italic>Streptomyces</jats:italic> spp., suggesting it may have a symbiotic relation with <jats:italic>Streptomyces</jats:italic>. Decreased <jats:italic>Bifidobacterium</jats:italic> levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of <jats:italic>Streptomyces</jats:italic> fermentation, is capable of feeding <jats:italic>Bifidobacterium</jats:italic>, thereby possibly preventing against COVID-19 susceptibilities. Moreover, <jats:italic>Bifidobacterium</jats:italic> may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.</jats:p>", "alternative-id": [ "10.3389/fmicb.2022.952321" ], "author": [ { "affiliation": [], "family": "Hazan", "given": "Sabine", "sequence": "first" } ], "container-title": "Frontiers in Microbiology", "container-title-short": "Front. Microbiol.", "content-domain": { "crossmark-restriction": true, "domain": [ "frontiersin.org" ] }, "created": { "date-parts": [ [ 2022, 7, 11 ] ], "date-time": "2022-07-11T06:22:09Z", "timestamp": 1657520529000 }, "deposited": { "date-parts": [ [ 2022, 7, 11 ] ], "date-time": "2022-07-11T06:22:15Z", "timestamp": 1657520535000 }, "indexed": { "date-parts": [ [ 2022, 7, 11 ] ], "date-time": "2022-07-11T06:43:08Z", "timestamp": 1657521788286 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 7, 11 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 7, 11 ] ], "date-time": "2022-07-11T00:00:00Z", "timestamp": 1657497600000 } } ], "link": [ { "URL": "https://www.frontiersin.org/articles/10.3389/fmicb.2022.952321/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1965", "original-title": [], "prefix": "10.3389", "published": { "date-parts": [ [ 2022, 7, 11 ] ] }, "published-online": { "date-parts": [ [ 2022, 7, 11 ] ] }, "publisher": "Frontiers Media SA", "reference": [ { "DOI": "10.36468/pharmaceutical-sciences.spl.416", "article-title": "The effect of ivermectin on reducing viral symptoms in patients with mild COVID-19.", "author": "Abbas", "doi-asserted-by": "publisher", "first-page": "87", "journal-title": "Indian J. Pharm. Sci.", "key": "B1", "volume": "83", "year": "2022" }, { "DOI": "10.1002/jmv.27122", "article-title": "Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study.", "author": "Abd-Elsalam", "doi-asserted-by": "publisher", "first-page": "5833", "journal-title": "J. Med. Virol.", "key": "B2", "volume": "93", "year": "2021" }, { "DOI": "10.1016/j.ijid.2020.11.191", "article-title": "A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.", "author": "Ahmed", "doi-asserted-by": "publisher", "first-page": "214", "journal-title": "Int. J. Infect. Dis.", "key": "B3", "volume": "103", "year": "2021" }, { "DOI": "10.7759/cureus.14761", "article-title": "Clinical variants, characteristics, and outcomes among COVID-19 patients: a case series analysis at a tertiary care hospital in Karachi, Pakistan.", "author": "Ahsan", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "B4", "volume": "13", "year": "2021" }, { "DOI": "10.24018/ejmed.2020.2.6.599", "article-title": "Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka – an observational study.", "author": "Alam", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Eur. J. Med. Health Sci.", "key": "B5", "volume": "2", "year": "2020" }, { "DOI": "10.3389/fmicb.2016.01204", "article-title": "Gut bifidobacteria populations in human health and aging.", "author": "Arboleya", "doi-asserted-by": "publisher", "journal-title": "Front. Microbiol.", "key": "B6", "volume": "7", "year": "2016" }, { "DOI": "10.2147/IJN.S313093", "article-title": "Clinical, biochemical and molecular evaluations of ivermectin mucoadhesivenanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19.", "author": "Aref", "doi-asserted-by": "publisher", "first-page": "4063", "journal-title": "Int. J. Nanomed.", "key": "B7", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.arcmed.2022.01.002", "article-title": "A multimodal strategy to reduce the risk of hospitalization/death in ambulatory patients with COVID-19.", "author": "Ascencio-Montiel", "doi-asserted-by": "publisher", "first-page": "323", "journal-title": "Arch. Med. Res.", "key": "B8", "volume": "53", "year": "2022" }, { "DOI": "10.1093/qjmed/hcab035", "article-title": "Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos.", "author": "Babalola", "doi-asserted-by": "publisher", "first-page": "780", "journal-title": "QJM Int. J. Med.", "key": "B9", "volume": "114", "year": "2022" }, { "author": "Barton", "journal-title": "Comprehensive Natural Products Chemistry", "key": "B10", "year": "1999" }, { "DOI": "10.1371/journal.pone.0247163", "article-title": "Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study.", "author": "Behera", "doi-asserted-by": "publisher", "journal-title": "PLoS One", "key": "B11", "volume": "16", "year": "2021" }, { "DOI": "10.3390/idr14020020", "article-title": "Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial.", "author": "Beltran Gonzalez", "doi-asserted-by": "publisher", "first-page": "160", "journal-title": "Infect. Dis. Rep.", "key": "B12", "volume": "14", "year": "2022" }, { "author": "Bernstein", "journal-title": "Second-Week Crash’ is Time of Peril for Some Covid-19 Patients.", "key": "B13", "year": "2020" }, { "DOI": "10.1177/20587384211059677", "article-title": "Oral booster probiotic bifidobacteria in SARS-COV-2 patients.", "author": "Bozkurt", "doi-asserted-by": "publisher", "journal-title": "Int. J. Immunopathol. Pharmacol.", "key": "B14", "volume": "35", "year": "2021" }, { "DOI": "10.1177/2058738420961304", "article-title": "The probiotic Bifidobacterium in the management of Coronavirus: a theoretical basis.", "author": "Bozkurt", "doi-asserted-by": "publisher", "journal-title": "Int. J. Immunopathol. Pharmacol.", "key": "B15", "volume": "34", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2021.106516", "article-title": "High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.", "author": "Buonfrate", "doi-asserted-by": "publisher", "journal-title": "Int. J. Antimicrob. Agents", "key": "B16", "volume": "59", "year": "2022" }, { "DOI": "10.1016/j.nmni.2021.100915", "article-title": "Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.", "author": "Cadegiani", "doi-asserted-by": "publisher", "journal-title": "New Microbes New Infect.", "key": "B17", "volume": "43", "year": "2021" }, { "DOI": "10.1093/femspd/ftx097", "article-title": "The gut–lung axis in tuberculosis.", "author": "Cervantes", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Pathog. Dis", "key": "B18", "volume": "75", "year": "2017" }, { "DOI": "10.1016/J.ECLINM.2020.100720", "article-title": "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial.", "author": "Chaccour", "doi-asserted-by": "publisher", "journal-title": "EClinicalMedicine", "key": "B19", "volume": "32", "year": "2021" }, { "DOI": "10.1097/MJT.0000000000001433", "article-title": "Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina.", "author": "Chahla", "doi-asserted-by": "publisher", "first-page": "e601", "journal-title": "Am. J. Ther.", "key": "B20", "volume": "28", "year": "2021" }, { "DOI": "10.14744/ejmo.2021.16263", "article-title": "A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients.", "author": "Chowdhury", "doi-asserted-by": "publisher", "first-page": "63", "journal-title": "Eurasian J. Med. Oncol.", "key": "B21", "volume": "5", "year": "2021" }, { "DOI": "10.1177/1753466620937170", "article-title": "Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection.", "author": "Conte", "doi-asserted-by": "publisher", "journal-title": "Ther. Adv. Respir. Dis.", "key": "B22", "volume": "14", "year": "2020" }, { "DOI": "10.1111/JAM.12415", "article-title": "Summer Meeting 2013: growth and physiology of bifidobacteria.", "author": "De Vuyst", "doi-asserted-by": "publisher", "first-page": "477", "journal-title": "J. Appl. Microbiol.", "key": "B23", "volume": "116", "year": "2014" }, { "DOI": "10.1016/J.ANAEROBE.2020.102247", "article-title": "FN3 protein fragment containing two type III fibronectin domains from B. longum GT15 binds to human tumor necrosis factor alpha in vitro.", "author": "Dyakov", "doi-asserted-by": "publisher", "journal-title": "Anaerobe", "key": "B24", "volume": "65", "year": "2020" }, { "DOI": "10.1002/jmv.26880", "article-title": "Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.", "author": "Elalfy", "doi-asserted-by": "publisher", "first-page": "3176", "journal-title": "J. Med. Virol.", "key": "B25", "volume": "93", "year": "2021" }, { "DOI": "10.29309/TPMJ/2021.28.05.5867", "article-title": "Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19.", "author": "Faisal", "doi-asserted-by": "publisher", "first-page": "737", "journal-title": "Prof. Med. J.", "key": "B26", "volume": "28", "year": "2021" }, { "DOI": "10.1590/1806-9282.20210661", "article-title": "Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience.", "author": "Ferreira", "doi-asserted-by": "publisher", "first-page": "1466", "journal-title": "Rev. Assoc. Médica Bras.", "key": "B27", "volume": "67", "year": "2021" }, { "journal-title": "STROMECTOL – Food and Drug Administration.", "key": "B28", "year": "2022" }, { "DOI": "10.1007/s10238-020-00671-y", "article-title": "Emerging treatment strategies for COVID-19 infection.", "author": "Gavriatopoulou", "doi-asserted-by": "publisher", "first-page": "167", "journal-title": "Clin. Exp. Med.", "key": "B29", "volume": "21", "year": "2021" }, { "DOI": "10.1080/19490976.2021.2018899", "article-title": "Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial.", "author": "Gutiérrez-Castrellón", "doi-asserted-by": "publisher", "journal-title": "Gut Microbes", "key": "B30", "volume": "14", "year": "2022" }, { "DOI": "10.1136/bmjgast-2022-000871", "article-title": "Lost microbes of COVID-19: Bifidobacterium,Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.", "author": "Hazan", "doi-asserted-by": "publisher", "journal-title": "BMJ Open Gastroenterol.", "key": "B31", "volume": "9", "year": "" }, { "DOI": "10.2217/FMB-2022-0014", "article-title": "Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.", "author": "Hazan", "doi-asserted-by": "publisher", "first-page": "339", "journal-title": "Future Microbiol.", "key": "B32", "volume": "17", "year": "" }, { "DOI": "10.1038/s41429-020-0336-z", "article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.", "author": "Heidary", "doi-asserted-by": "publisher", "first-page": "593", "journal-title": "J. Antibiot. (Tokyo)", "key": "B33", "volume": "73", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.106248", "article-title": "A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin.", "author": "Hellwig", "doi-asserted-by": "publisher", "journal-title": "Int. J. Antimicrob. Agents", "key": "B34", "volume": "57", "year": "2021" }, { "DOI": "10.1098/RSOB.160155", "article-title": "Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner.", "author": "Hughes", "doi-asserted-by": "publisher", "journal-title": "Open Biol.", "key": "B35", "volume": "7", "year": "2017" }, { "DOI": "10.3390/NU13093172", "article-title": "Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic.", "author": "Jabczyk", "doi-asserted-by": "publisher", "journal-title": "Nutrients", "key": "B36", "volume": "13", "year": "2021" }, { "DOI": "10.1080/21645515.2021.1995283", "article-title": "Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?", "author": "Joshi", "doi-asserted-by": "publisher", "first-page": "4714", "journal-title": "Hum. Vaccines Immunother.", "key": "B37", "volume": "17", "year": "2021" }, { "DOI": "10.7759/cureus.21272", "article-title": "Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching.", "author": "Kerr", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "B38", "volume": "14", "year": "2022" }, { "DOI": "10.1016/j.sjbs.2020.11.025", "article-title": "Probiotics, prebiotics, and COVID-19 infection: a review article.", "author": "Khaled", "doi-asserted-by": "publisher", "first-page": "865", "journal-title": "Saudi J. Biol. Sci.", "key": "B39", "volume": "28", "year": "2021" }, { "DOI": "10.1016/j.arbres.2020.08.007", "article-title": "Ivermectin treatment may improve the prognosis of patients with COVID-19.", "author": "Khan", "doi-asserted-by": "publisher", "first-page": "828", "journal-title": "Arch. Bronconeumol.", "key": "B40", "volume": "56", "year": "2020" }, { "DOI": "10.1055/s-0041-1726461", "article-title": "Inclusion of cephalexin in COVID-19 treatment combinations may prevent lung involvement in mild infections: a case report with pharmacological genomics perspective.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "first-page": "078", "journal-title": "Glob. Med. Genet.", "key": "B41", "volume": "8", "year": "2021" }, { "DOI": "10.1055/s-0041-1735538", "article-title": "Impact of SARS-CoV-2 genetic blueprints on the oral manifestation of COVID-19: a case report.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "first-page": "183", "journal-title": "Glob. Med. Genet.", "key": "B42", "volume": "8", "year": "" }, { "DOI": "10.3389/fmicb.2022.718786", "article-title": "Potential of Bacillus subtilis against SARS-CoV-2 – a sustainable drug development perspective.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "journal-title": "Front. Microbiol.", "key": "B43", "volume": "13", "year": "2022" }, { "DOI": "10.3934/molsci.2020013", "article-title": "SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "first-page": "281", "journal-title": "AIMS Mol. Sci.", "key": "B44", "volume": "7", "year": "2020" }, { "DOI": "10.1055/s-0041-1723086", "article-title": "Potential of CRISPR/Cas13 system in treatment and diagnosis of COVID-19.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "first-page": "007", "journal-title": "Glob. Med. Genet.", "key": "B45", "volume": "8", "year": "" }, { "DOI": "10.1055/s-0041-1725143", "article-title": "Concise update on genomics of COVID-19: approach to its latest mutations, escalated contagiousness, and vaccine resistance.", "author": "Khodavirdipour", "doi-asserted-by": "publisher", "first-page": "085", "journal-title": "Glob. Med. Genet.", "key": "B46", "volume": "8", "year": "" }, { "DOI": "10.1111/fcp.12644", "article-title": "A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin’s possible mode of action against SARS-CoV-2.", "author": "Kinobe", "doi-asserted-by": "publisher", "first-page": "260", "journal-title": "Fundam. Clin. Pharmacol.", "key": "B47", "volume": "35", "year": "2021" }, { "DOI": "10.36106/paripex/4801859", "article-title": "Ivermectin as adjuvant to hydroxycholoroquine in patients resistant to standard treatment for Sars-Cov-2: results of an open-label randomized clinical study.", "author": "Kishoria", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Paripex Indian J. Res.", "key": "B48", "volume": "9", "year": "2020" }, { "DOI": "10.1016/j.eclinm.2021.100959", "article-title": "Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial.", "author": "Krolewiecki", "doi-asserted-by": "publisher", "journal-title": "eClinicalMedicine", "key": "B49", "volume": "37", "year": "2021" }, { "DOI": "10.1016/j.pt.2017.02.004", "article-title": "Ivermectin – old drug, new tricks?", "author": "Laing", "doi-asserted-by": "publisher", "first-page": "463", "journal-title": "Trends Parasitol.", "key": "B50", "volume": "33", "year": "2017" }, { "DOI": "10.1007/s12602-012-9093-z", "article-title": "antagonistic action of lactobacilli and bifidobacteria in relation to Staphylococcus aureus and their influence on the immune response in cases of intravaginal Staphylococcosis in mice.", "author": "Lazarenko", "doi-asserted-by": "publisher", "first-page": "78", "journal-title": "Probiotics Antimicrob. Proteins", "key": "B51", "volume": "4", "year": "2012" }, { "DOI": "10.21873/invivo.12134", "article-title": "Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2.", "author": "Lehrer", "doi-asserted-by": "publisher", "first-page": "3023", "journal-title": "In Vivo", "key": "B52", "volume": "34", "year": "2020" }, { "DOI": "10.4014/JMB.2007.07046", "article-title": "Antimicrobial and immunomodulatory effects of Bifidobacterium strains: a review.", "author": "Lim", "doi-asserted-by": "publisher", "first-page": "1793", "journal-title": "J. Microbiol. Biotechnol.", "key": "B53", "volume": "30", "year": "2020" }, { "DOI": "10.1001/jamainternmed.2022.0189", "article-title": "Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial.", "author": "Lim", "doi-asserted-by": "publisher", "journal-title": "JAMA Intern. Med.", "key": "B54", "volume": "182", "year": "2022" }, { "DOI": "10.1016/j.ijid.2021.02.014", "article-title": "Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.", "author": "Lima-Morales", "doi-asserted-by": "publisher", "first-page": "598", "journal-title": "Int. J. Infect. Dis.", "key": "B55", "volume": "105", "year": "2021" }, { "DOI": "10.1001/jama.2021.3071", "article-title": "Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial.", "author": "López-Medina", "doi-asserted-by": "publisher", "journal-title": "JAMA", "key": "B56", "volume": "325", "year": "2021" }, { "DOI": "10.3390/nu9091021", "article-title": "Effects of probiotics, prebiotics, and synbiotics on human health.", "author": "Markowiak", "doi-asserted-by": "publisher", "journal-title": "Nutrients", "key": "B57", "volume": "9", "year": "2017" }, { "DOI": "10.3389/fpubh.2022.813378", "article-title": "Safety and efficacy of a MEURI program for the use of high dose ivermectin in COVID-19 patients.", "author": "Mayer", "doi-asserted-by": "publisher", "journal-title": "Front. Public Health", "key": "B58", "volume": "10", "year": "2022" }, { "DOI": "10.1097/BOR.0000000000000822", "article-title": "Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatorydebate.", "author": "Mehta", "doi-asserted-by": "publisher", "first-page": "419", "journal-title": "Curr. Opin. Rheumatol.", "key": "B59", "volume": "33", "year": "2021" }, { "DOI": "10.1016/j.jiac.2021.08.021", "article-title": "Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial.", "author": "Mohan", "doi-asserted-by": "publisher", "first-page": "1743", "journal-title": "J. Infect. Chemother.", "key": "B60", "volume": "27", "year": "2021" }, { "DOI": "10.1016/j.pt.2015.10.008", "article-title": "Reflections on the nobel prize for medicine 2015 – the public health legacy and impact of Avermectin and Artemisinin.", "author": "Molyneux", "doi-asserted-by": "publisher", "first-page": "605", "journal-title": "Trends Parasitol.", "key": "B61", "volume": "31", "year": "2015" }, { "DOI": "10.7759/cureus.17455", "article-title": "Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers: a propensity score-matched retrospective cohort study.", "author": "Morgenstern", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "B62", "volume": "13", "year": "2021" }, { "DOI": "10.46998/IJCMCR.2021.13.000320", "article-title": "Ivermectin use associated with reduced duration of Covid-19 febrile illness in a community setting.", "author": "Mukarram", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Int. J. Clin. Stud. Med. Case Rep.", "key": "B63", "volume": "13", "year": "2021" }, { "DOI": "10.1016/j.rcsop.2021.100101", "article-title": "Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan.", "author": "Mustafa", "doi-asserted-by": "publisher", "journal-title": "Explor. Res. Clin. Soc. Pharm.", "key": "B64", "volume": "5", "year": "2022" }, { "DOI": "10.1186/s12879-021-06104-9", "article-title": "Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.", "author": "Okumuş", "doi-asserted-by": "publisher", "journal-title": "BMC Infect. Dis.", "key": "B65", "volume": "21", "year": "2021" }, { "DOI": "10.1016/j.pt.2014.07.005", "article-title": "Ivermectin: panacea for resource-poor communities?", "author": "Ômura", "doi-asserted-by": "publisher", "first-page": "445", "journal-title": "Trends Parasitol.", "key": "B66", "volume": "30", "year": "2014" }, { "DOI": "10.1002/jmv.27469", "article-title": "Effectiveness and safety of Ivermectin in COVID-19 patients: a prospective study at a safety-net hospital.", "author": "Ozer", "doi-asserted-by": "publisher", "first-page": "1473", "journal-title": "J. Med. Virol.", "key": "B67", "volume": "94", "year": "2022" }, { "DOI": "10.3329/imcjms.v14i2.52826", "article-title": "Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.", "author": "Podder", "doi-asserted-by": "publisher", "first-page": "11", "journal-title": "IMC J. Med. Sci.", "key": "B68", "volume": "14", "year": "2021" }, { "DOI": "10.1016/j.chest.2020.10.009", "article-title": "Use of ivermectin is associated with lower mortality in hospitalized patients with Coronavirus disease 2019.", "author": "Rajter", "doi-asserted-by": "publisher", "first-page": "85", "journal-title": "Chest", "key": "B69", "volume": "159", "year": "2021" }, { "DOI": "10.18433/jpps32105", "article-title": "Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.", "author": "Ravikirti", "doi-asserted-by": "publisher", "first-page": "343", "journal-title": "J. Pharm. Pharm. Sci.", "key": "B70", "volume": "24", "year": "2021" }, { "DOI": "10.5061/DRYAD.QJQ2BVQF6", "article-title": "Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.", "author": "Reaz", "doi-asserted-by": "publisher", "journal-title": "J. Int. Med. Res.", "key": "B71", "volume": "49", "year": "2020" }, { "DOI": "10.3389/fcimb.2021.747816", "article-title": "A pro-inflammatory gut microbiome characterizes SARS-CoV-2 infected patients and a reduction in the connectivity of an anti-inflammatory bacterial network associates with severe COVID-19.", "author": "Reinold", "doi-asserted-by": "publisher", "journal-title": "Front. Cell. Infect. Microbiol.", "key": "B72", "volume": "11", "year": "2021" }, { "DOI": "10.1056/NEJMoa2115869", "article-title": "Effect of early treatment with ivermectin among patients with Covid-19.", "author": "Reis", "doi-asserted-by": "publisher", "first-page": "1721", "journal-title": "N. Engl. J. Med.", "key": "B73", "volume": "386", "year": "2022" }, { "DOI": "10.21608/zumj.2021.92746.2329", "article-title": "miRNA-223-3p, miRNA- 2909 and cytokines expression in COVID-19 patients treated with ivermectin.", "author": "Rezk", "doi-asserted-by": "publisher", "first-page": "573", "journal-title": "Zagazig Univ. Med. J.", "key": "B74", "volume": "28", "year": "2021" }, { "DOI": "10.3389/fmicb.2016.00979", "article-title": "Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut.", "author": "Rivière", "doi-asserted-by": "publisher", "journal-title": "Front. Microbiol.", "key": "B75", "volume": "7", "year": "2016" }, { "DOI": "10.1007/s00210-020-01902-5", "article-title": "Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.", "author": "Rizzo", "doi-asserted-by": "publisher", "first-page": "1153", "journal-title": "Naunyn. Schmiedebergs Arch. Pharmacol.", "key": "B76", "volume": "393", "year": "2020" }, { "DOI": "10.3389/fmicb.2017.02345", "article-title": "Bifidobacteria and their molecular communication with the immune system.", "author": "Ruiz", "doi-asserted-by": "publisher", "journal-title": "Front. Microbiol.", "key": "B77", "volume": "8", "year": "2017" }, { "DOI": "10.1007/s11224-021-01776-0", "article-title": "The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.", "author": "Saha", "doi-asserted-by": "publisher", "first-page": "1985", "journal-title": "Struct. Chem.", "key": "B78", "volume": "32", "year": "2021" }, { "DOI": "10.1016/j.ijid.2021.04.035", "article-title": "Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial.", "author": "Seet", "doi-asserted-by": "publisher", "first-page": "314", "journal-title": "Int. J. Infect. Dis.", "key": "B79", "volume": "106", "year": "2021" }, { "DOI": "10.1111/j.1574-6976.2011.00313.x", "article-title": "Streptomyces as symbionts: an emerging and widespread theme?", "author": "Seipke", "doi-asserted-by": "publisher", "first-page": "862", "journal-title": "FEMS Microbiol. Rev.", "key": "B80", "volume": "36", "year": "2012" }, { "DOI": "10.1016/j.clinthera.2021.04.007", "article-title": "Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial.", "author": "Shahbaznejad", "doi-asserted-by": "publisher", "first-page": "1007", "journal-title": "Clin. Ther.", "key": "B81", "volume": "43", "year": "2021" }, { "DOI": "10.3390/v13020202", "article-title": "COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention.", "author": "Sharma", "doi-asserted-by": "publisher", "journal-title": "Viruses", "key": "B82", "volume": "13", "year": "2021" }, { "DOI": "10.1016/j.jiac.2021.12.024", "article-title": "Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: a propensity score analysis.", "author": "Shimizu", "doi-asserted-by": "publisher", "first-page": "548", "journal-title": "J. Infect. Chemother.", "key": "B83", "volume": "28", "year": "2022" }, { "DOI": "10.7860/JCDR/2021/46795.14529", "article-title": "Use of ivermectin as a potential chemoprophylaxis for COVID-19 in egypt: a randomised clinical trial.", "author": "Shoumann", "doi-asserted-by": "publisher", "first-page": "OC27", "journal-title": "J. Clin. Diagn. Res.", "key": "B84", "volume": "15", "year": "2021" }, { "DOI": "10.1016/j.medmic.2020.100023", "article-title": "Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18.", "author": "Tao", "doi-asserted-by": "publisher", "journal-title": "Med. Microecol.", "key": "B85", "volume": "5", "year": "2020" }, { "article-title": "[Management of corona virus disease-19 (COVID-19): the Zhejiang experience].", "author": "Xu", "first-page": "147", "journal-title": "Zhejiang XueXueBao Yi Xue Ban J. Zhejiang Univ. Med. Sci.", "key": "B86", "volume": "49", "year": "2020" }, { "DOI": "10.1136/gutjnl-2020-323020", "article-title": "Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.", "author": "Yeoh", "doi-asserted-by": "publisher", "first-page": "698", "journal-title": "Gut", "key": "B87", "volume": "70", "year": "2021" }, { "DOI": "10.1016/j.nmni.2020.100815", "article-title": "Natural history of COVID-19: back to basics.", "author": "Zayet", "doi-asserted-by": "publisher", "journal-title": "New Microbes New Infect.", "key": "B88", "volume": "38", "year": "2020" }, { "DOI": "10.1021/JA065950K", "article-title": "The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility.", "author": "Zhang", "doi-asserted-by": "publisher", "first-page": "16420", "journal-title": "J. Am. Chem. Soc.", "key": "B89", "volume": "128", "year": "2006" }, { "DOI": "10.4081/monaldi.2022.2062", "article-title": "The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness.", "author": "Zubair", "doi-asserted-by": "publisher", "journal-title": "Monaldi Arch. Chest Dis.", "key": "B90", "year": "2022" }, { "DOI": "10.1016/j.gpb.2021.09.004", "article-title": "Gut microbiome alterations in COVID-19.", "author": "Zuo", "doi-asserted-by": "crossref", "first-page": "679", "journal-title": "Genomics Proteomics Bioinformatics", "key": "B91", "volume": "19", "year": "2021" } ], "reference-count": 91, "references-count": 91, "relation": {}, "resource": { "primary": { "URL": "https://www.frontiersin.org/articles/10.3389/fmicb.2022.952321/full" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Microbiology (medical)", "Microbiology" ], "subtitle": [], "title": "Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity", "type": "journal-article", "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "volume": "13" }